Great Basin Scientific, Inc. GBSN, a molecular diagnostics
company, today announced that the United States Patent and Trademark
Office (USPTO) issued U.S.
Patent 9200312 for the Company's compositions for signal
amplification. The underlying technology improves assay sensitivity;
provides for detection of pathogens directly from clinical specimens
such as blood, lung aspirates, urine, stool and swabs at low levels,
without the need for time consuming and expensive techniques such as
PCR; and can be utilized with all potential diagnostic targets,
including nucleic acids and proteins. The patent protects development of
highly-sensitive immunoassay-based testing with expanded targets on the
Great Basin testing platform.
"Great Basin is committed to protecting
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in